[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07594496":3,"trial-entities:NCT07594496":78,"trial-summary:NCT07594496":81},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":6,"overall_status":7,"completion_date":8,"status_verified_date":9,"last_update_date":10,"start_date":11,"sponsor_name":12,"lead_sponsor_class":13,"has_dmc":14,"brief_summary":15,"detailed_description":16,"conditions":17,"keywords":20,"study_type":21,"primary_purpose":16,"phases":22,"enrollment_info":23,"interventions":26,"primary_outcomes":32,"secondary_outcomes":41,"sex":45,"minimum_age":46,"maximum_age":16,"healthy_volunteers":14,"eligibility_criteria":47,"std_ages":53,"locations":56,"central_contacts":66,"overall_officials":67,"references":73,"see_also_links":74},"NCT07594496","25-011419","Prevalence and Clinical Manifestations of Cannabis Withdrawal in Hospitalized Patients With Hematological Malignancies Undergoing Bone Marrow Transplant (BMT) or Chimeric Antigen Receptor T-Cell (CAR-T) Therapy","ENROLLING_BY_INVITATION","2031-02-28","2026-05","2026-05-18","2026-02-18","Mayo Clinic","OTHER",false,"This study evaluates the prevalence of cannabis withdrawal and the clinical manifestations of cannabis withdrawal syndrome in patients hospitalized for BMT or CAR-T therapy.",null,[18,19],"Hematopoietic and Lymphatic System Neoplasm","Malignant Solid Neoplasm",[],"OBSERVATIONAL",[],{"count":24,"type":25},300,"ESTIMATED",[27],{"type":13,"name":28,"description":29,"armGroupLabels":30},"Non-Interventional Study","Non-interventional study",[31],"Observational",[33,37],{"measure":34,"description":35,"timeFrame":36},"Prevalence of cannabis withdrawal","Descriptive statistics will be utilized to summarize cannabis withdrawal prevalence.","Up to 1 year",{"measure":38,"description":39,"timeFrame":40},"Severity of withdrawal symptoms","Assessed by the Cannabis Withdrawal Scale (CWS), a self-report instrument used measures the intensity of 19 cannabis withdrawal symptoms over the last 24 hours. Each item is rated on a 10-point Likert scale where 0=not al all and 10=extremely. Items are rated twice, first for intensity of symptom and then for negative impact on daily activity. Withdrawal symptom scores range from 0 to 190, with higher scores reflecting greater intensity of withdrawal symptoms.","Daily for first 4 days of hospitalization",[42],{"measure":43,"description":44,"timeFrame":36},"Mortality Rate","Assessed for all-cause, in-hospital, and post-hospitalization mortality rates by review of the electronic medical record.","ALL","18 Years",{"inclusion":48,"exclusion":50,"raw_text":52},[49],"All adult patients admitted for BMT or CAR-T therapy",[51],"Individuals unable to provide informed consent","Inclusion Criteria:\n\n* All adult patients admitted for BMT or CAR-T therapy\n\nExclusion Criteria:\n\n* Individuals unable to provide informed consent",[54,55],"ADULT","OLDER_ADULT",[57],{"facility":58,"city":59,"state":60,"zip":61,"country":62,"geoPoint":63},"Mayo Clinic in Arizona","Scottsdale","Arizona","85259","United States",{"lat":64,"lon":65},33.50921,-111.89903,[],[68,71],{"name":69,"affiliation":12,"role":70},"Osama A. Abulseoud, MD","PRINCIPAL_INVESTIGATOR",{"name":72,"affiliation":12,"role":70},"Sondra Schultz, MD",[],[75],{"label":76,"url":77},"Mayo Clinic Clinical Trials","https:\u002F\u002Fwww.mayo.edu\u002Fresearch\u002Fclinical-trials",{"nct_id":4,"conditions":79,"biomarkers":80},[18,19],[],{"nct_id":4,"found":14,"summary":16,"prompt_version":16}]